Madrigal Pharmaceuticals struck a licensing deal with Ribo Life Science (and Ribocure) to acquire global rights to six preclinical siRNA programs targeting metabolic dysfunction‑associated steatohepatitis (MASH). Ribo will receive $60 million upfront and is eligible for up to $4.4 billion in development, regulatory and commercial milestones plus royalties. The agreement leverages Ribo’s GalSTARTM delivery and siRNA chemistry platforms and expands Madrigal’s MASH portfolio beyond its existing small‑molecule franchise. Both companies highlighted bi‑specific siRNA potential and the strategic fit with Madrigal’s commercial capabilities. The deal signals continued large‑scale investment in MASH therapeutics and validates siRNA as a competitive modality in the liver disease space.